Insulin Lispro (Humalog) Injectable Suppliers & Bulk Manufacturers

Available Forms: Vials/pens

Available Strengths: U-100, U-200

Reference Brands: Humalog, Admelog, Fiasp(US); Humalog, Fiasp(EU)

Category: Diabetes

Insulin Lispro (Humalog) is a rapid-acting insulin that quickly mimics natural insulin release post-meal. It lowers blood sugar rapidly, providing flexible dosing around mealtimes. Benefits include quick onset, precise glucose control, reduced post-meal hyperglycemia, and improved convenience for insulin therapy, essential for effective management of diabetes.

Product Description:

Insulin Lispro (Humalog) is a rapid-acting insulin approved in the EU and US for post-meal blood glucose control. In the EU, Novo Nordisk’s Fiasp, a faster-acting version, is regulated by EMA with dossiers demonstrating safety, efficacy, and manufacturing quality. In the US, the FDA has approved Humalog and biosimilars like Admelog based on comprehensive clinical data, biosimilarity, and ongoing pharmacovigilance. Both regions require detailed regulatory dossiers for approval and post-marketing safety monitoring. For expert assistance with pharmaceutical dossiers and compliance, visit PharmaTradz, your trusted partner in regulatory solutions.